-
公开(公告)号:US20120034250A1
公开(公告)日:2012-02-09
申请号:US13264008
申请日:2010-04-13
申请人: Shohei Shirakami , Yutaka Nakajima , Jun Maeda , Hiroaki Tominaga , Hiroaki Yamagishi , Takeshi Hondo , Masamichi Inami , Hiroki Morio , Takayuki Inoue , Tsuyoshi Mizutani , Hiroki Ishioka
发明人: Shohei Shirakami , Yutaka Nakajima , Jun Maeda , Hiroaki Tominaga , Hiroaki Yamagishi , Takeshi Hondo , Masamichi Inami , Hiroki Morio , Takayuki Inoue , Tsuyoshi Mizutani , Hiroki Ishioka
IPC分类号: A61K31/437 , A61K31/55 , A61P37/06 , A61K31/541 , A61K31/5377 , A61K31/496 , C07D471/14 , A61K31/497
CPC分类号: C07D471/14 , C07D519/00
摘要: [Problem]The present invention provides a condensed pyrrolopyridine derivative which is useful as an active ingredient for a pharmaceutical composition, in particular, a pharmaceutical composition for preventing or treating diseases caused by undesirable cytokine signal transduction or diseases caused by abnormal cytokine signal transduction.[Means for Solution]The present inventors have extensively studied a compound having a JAK inhibitory action, and as a result, they have found that a condensed pyrrolopyridine derivative which is the compound of the present invention has an excellent JAK inhibitory action, and is therefore useful as an agent for preventing or treating diseases caused by undesirable cytokine signal transduction or diseases caused by abnormal cytokine signal transduction, thereby completing the present invention.
摘要翻译: 本发明提供可用作药物组合物的活性成分的特别是用于预防或治疗由不良细胞因子信号转导引起的疾病或由异常细胞因子信号转导引起的疾病的药物组合物的缩合吡咯并吡啶衍生物。 [解决方案]本发明人广泛研究了具有JAK抑制作用的化合物,结果发现,作为本发明化合物的缩合吡咯并吡啶衍生物具有优异的JAK抑制作用,因此 可用作预防或治疗由不良细胞因子信号转导引起的疾病或由异常细胞因子信号转导引起的疾病的药剂,从而完成本发明。
-
公开(公告)号:US20110230467A1
公开(公告)日:2011-09-22
申请号:US13130527
申请日:2009-11-20
申请人: Shohei Shirakami , Fumie Takahashi , Yutaka Nakajima , Hirofumi Omura , Naohiro Aoyama , Hiroshi Sasaki , Takeshi Hondo , Hiroaki Tominaga
发明人: Shohei Shirakami , Fumie Takahashi , Yutaka Nakajima , Hirofumi Omura , Naohiro Aoyama , Hiroshi Sasaki , Takeshi Hondo , Hiroaki Tominaga
IPC分类号: A61K31/55 , A61K31/5513 , A61K31/5377 , A61P43/00 , A61K31/497 , A61K31/506 , A61K31/444 , A61K31/4439 , C07D401/14 , C07D413/14 , C07D401/12 , C07D417/14 , C07D409/14 , C07D401/00
CPC分类号: C07D401/12 , C07D213/82 , C07D401/14 , C07D405/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/14 , C07D471/10
摘要: [Problem] The present invention provides a 4,6-diaminonicotinamide compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for treating diseases caused by undesirable and/or abnormal cytokine signal transduction.[Means for Solution] The present inventors have extensively studied compounds having a JAK3 inhibitory action, and as a result, they have found that a 4,6-diaminonicotinamide compound which is the compound of the present invention has an excellent JAK3 inhibitory action and is useful as an agent for preventing or treating diseases caused by undesirable and/or abnormal cytokine signal transduction, thereby completing the present invention.
摘要翻译: 本发明提供了可用作药物组合物的活性成分的特征的4,6-二氨基烟酰胺化合物,特别是用于治疗由不希望的和/或异常的细胞因子信号转导引起的疾病的药物组合物。 [解决方案]本发明人广泛研究了具有JAK3抑制作用的化合物,结果发现作为本发明化合物的4,6-二氨基烟酰胺化合物具有优异的JAK3抑制作用, 可用作预防或治疗由不良和/或异常细胞因子信号转导引起的疾病的药剂,从而完成本发明。
-
公开(公告)号:US20090264399A1
公开(公告)日:2009-10-22
申请号:US11995445
申请日:2006-07-13
申请人: Takayuki Inoue , Takashi Tojo , Masataka Morita , Yutaka Nakajima , Keiko Hatanaka , Shohei Shirakami , Hiroshi Sasaki , Akira Tanaka , Fumie Takahashi , Koichiro Mukoyoshi , Yasuyuki Higashi , Akira Okimoto , Takeshi Hondo , Hitoshi Sawada
发明人: Takayuki Inoue , Takashi Tojo , Masataka Morita , Yutaka Nakajima , Keiko Hatanaka , Shohei Shirakami , Hiroshi Sasaki , Akira Tanaka , Fumie Takahashi , Koichiro Mukoyoshi , Yasuyuki Higashi , Akira Okimoto , Takeshi Hondo , Hitoshi Sawada
IPC分类号: A61K31/437 , C07D471/04 , C07D413/14 , C07D471/14 , A61K31/5377 , A61K31/397 , A61P25/00 , A61P37/06 , A61P35/00 , A61P35/02 , A61P11/06
CPC分类号: C07D471/14 , C07D519/00
摘要: The invention relates to compound of the formula (I) or its salt, wherein —R1, —R2, —R3, —R4, —R5, -M-, —X— and —Y═ are as defined in the description, their use of as, medicament, the process for their preparation and use for the treatment of JAK3 mediated diseases.
摘要翻译: 本发明涉及式(I)或其盐的化合物,其中-R1,-R2,-R3,-R4,-R5,-M-,-X-和-Y-如说明书中所定义,它们 使用as,药物,其制备方法和用于治疗JAK3介导的疾病。
-
公开(公告)号:US08163767B2
公开(公告)日:2012-04-24
申请号:US11995445
申请日:2006-07-13
申请人: Takayuki Inoue , Takashi Tojo , Masataka Morita , Yutaka Nakajima , Keiko Hatanaka , Shohei Shirakami , Hiroshi Sasaki , Akira Tanaka , Fumie Takahashi , Koichiro Mukoyoshi , Yasuyuki Higashi , Akira Okimoto , Takeshi Hondo , Hitoshi Sawada
发明人: Takayuki Inoue , Takashi Tojo , Masataka Morita , Yutaka Nakajima , Keiko Hatanaka , Shohei Shirakami , Hiroshi Sasaki , Akira Tanaka , Fumie Takahashi , Koichiro Mukoyoshi , Yasuyuki Higashi , Akira Okimoto , Takeshi Hondo , Hitoshi Sawada
IPC分类号: A61K31/44 , C07D471/14
CPC分类号: C07D471/14 , C07D519/00
摘要: The invention relates to compound of the formula (I) or its salt, wherein —R1, —R2, —R3, —R4, —R5, -M-, —X— and —Y═ are as defined in the description, their use of as, medicament, the process for their preparation and use for the treatment of JAK3 mediated diseases.
摘要翻译: 本发明涉及式(I)化合物或其盐,其中-R1,-R2,-R3,-R4,-R5,-M-,-X-和-Y =如说明书中所定义,它们 使用as,药物,其制备方法和用于治疗JAK3介导的疾病。
-
公开(公告)号:US20100054654A1
公开(公告)日:2010-03-04
申请号:US11884407
申请日:2006-02-16
申请人: Kenji Kawano , Masaya Nanami , Hiroaki Senda , Takeshi Hondo , Seiji Uchida , Yuji Sato , Toru Nakahira
发明人: Kenji Kawano , Masaya Nanami , Hiroaki Senda , Takeshi Hondo , Seiji Uchida , Yuji Sato , Toru Nakahira
CPC分类号: G02F1/2255 , G02F1/0356 , G02F2001/212 , G02F2202/07 , G02F2202/20
摘要: Herein disclosed is an optical modulation device, comprising: a substrate 1 having a polarization non-reversal region 17a and a polarization reversal region 17b; an optical waveguide 18 including first and second branched optical waveguide portions 18a, 18b; and a traveling waveguide including a center electrode 19a and a ground electrode 19b, 19c to have an electric signal applied thereto, said traveling waveguide and said first and second branched optical waveguide portions collectively forming an interaction portion to have said incident light interacted with said electric signal, said interaction portion being constituted by a first interaction sub-portion 20a and a second interaction sub-portion 20b, said first and second interaction sub-portions being respectively positioned in regions of said substrate having opposite polarization orientations with each other, in which said center electrode is positioned in face to face relationship with one of said first and second branched optical waveguide portions at said first and second interaction sub-portion to ensure that said incident light in said first and second branched optical waveguide portions are phase modulated, and in which said interaction portion includes an optical waveguide shift sub-portion sandwiched between said first and second interaction sub-portions to have positions of said first and second branched optical waveguide portions shifted therein in a transverse direction, ensuring that positions of said first and second optical waveguides relative to said center and ground electrodes are interchanged between said first and second interaction sub-portions.
摘要翻译: 这里公开了一种光调制装置,包括:具有极化非反转区域17a和极化反转区域17b的基板1; 包括第一和第二分支光波导部分18a,18b的光波导18; 以及具有施加电信号的中心电极19a和接地电极19b,19c的行进波导,所述行波导管和所述第一和第二分支光波导部分共同形成相互作用部分,以使所述入射光与所述电 信号,所述相互作用部分由第一相互作用子部分20a和第二相互作用子部分20b构成,所述第一相互作用子部分和第二相互作用子部分分别位于具有相反极化取向的所述基板的区域中,其中 所述中心电极在所述第一和第二相互作用子部分处于与所述第一和第二分支光波导部分中的一个相对面的关系,以确保所述第一和第二分支光波导部分中的所述入射光被相位调制,以及 其中所述相互作用部分包括光波导s 夹在所述第一相互作用子部分和第二相互作用子部分之间的折叠部分,以使所述第一和第二分支光波导部分在横向方向上移位的位置,确保所述第一和第二光波导相对于所述中心和接地电极的位置 在所述第一和第二相互作用子部分之间互换。
-
公开(公告)号:US20140378459A1
公开(公告)日:2014-12-25
申请号:US14344377
申请日:2012-09-14
申请人: Jiro Fujiyasu , Kazuhiko Ohne , Susumu Yamaki , Tomoyoshi Imaizumi , Takeshi Hondo , Keisuke Matsuura , Tomohki Satou , Satoshi Sasamura
发明人: Jiro Fujiyasu , Kazuhiko Ohne , Susumu Yamaki , Tomoyoshi Imaizumi , Takeshi Hondo , Keisuke Matsuura , Tomohki Satou , Satoshi Sasamura
IPC分类号: C07C279/18 , C07D215/48 , C07D209/42 , C07D295/13 , C07D333/40 , C07D257/04 , C07D271/07 , C07D233/64 , C07D217/26
CPC分类号: C07C279/18 , C07B2200/07 , C07C2601/02 , C07C2601/14 , C07D207/16 , C07D209/20 , C07D209/42 , C07D211/62 , C07D213/79 , C07D215/20 , C07D215/48 , C07D215/50 , C07D217/26 , C07D233/64 , C07D257/04 , C07D271/06 , C07D271/07 , C07D277/20 , C07D277/56 , C07D295/12 , C07D295/13 , C07D333/38 , C07D333/40
摘要: [Problem]Provided is a compound which is useful as an agent for preventing and/or treating renal diseases. [Means for Solution]The present inventors have conducted extensive studies on compounds having a trypsin inhibitory action, and as a result, they have found that a guanidinobenzoic acid compound has a trypsin inhibitory action, thereby completing the present invention. The guanidinobenzoic acid compound of the present invention can be used as an agent for preventing and/or treating renal disease as an agent which will substitute low-protein diet therapy, and an agent for preventing and/or treating trypsin-related diseases, for example, pancreatitis, gastroesophageal reflux disease, hepatic encephalopathy, influenza, and the like.
摘要翻译: [问题]提供可用作预防和/或治疗肾脏疾病的药剂的化合物。 [解决方案]本发明人对具有胰蛋白酶抑制作用的化合物进行了广泛的研究,结果发现胍基苯甲酸化合物具有胰蛋白酶抑制作用,从而完成了本发明。 本发明的胍基苯甲酸化合物可以用作预防和/或治疗肾脏疾病的药剂,作为代替低蛋白饮食疗法的药剂,以及用于预防和/或治疗胰蛋白酶相关疾病的药剂,例如 ,胰腺炎,胃食管反流病,肝性脑病,流行性感冒等。
-
公开(公告)号:US09199927B2
公开(公告)日:2015-12-01
申请号:US14344377
申请日:2012-09-14
申请人: Jiro Fujiyasu , Kazuhiko Ohne , Susumu Yamaki , Tomoyoshi Imaizumi , Takeshi Hondo , Keisuke Matsuura , Tomohki Satou , Satoshi Sasamura
发明人: Jiro Fujiyasu , Kazuhiko Ohne , Susumu Yamaki , Tomoyoshi Imaizumi , Takeshi Hondo , Keisuke Matsuura , Tomohki Satou , Satoshi Sasamura
IPC分类号: A61K31/47 , C07C229/02 , C07D215/38 , C07C279/18 , C07D213/79 , C07D215/20 , C07D215/48 , C07D215/50 , C07D333/38 , C07D333/40 , C07D233/64 , C07D257/04 , C07D271/06 , C07D207/16 , C07D277/20 , C07D277/56 , C07D209/20 , C07D209/42 , C07D295/12 , C07D211/62 , C07D217/26 , C07D271/07 , C07D295/13
CPC分类号: C07C279/18 , C07B2200/07 , C07C2601/02 , C07C2601/14 , C07D207/16 , C07D209/20 , C07D209/42 , C07D211/62 , C07D213/79 , C07D215/20 , C07D215/48 , C07D215/50 , C07D217/26 , C07D233/64 , C07D257/04 , C07D271/06 , C07D271/07 , C07D277/20 , C07D277/56 , C07D295/12 , C07D295/13 , C07D333/38 , C07D333/40
摘要: [Problem]Provided is a compound which is useful as an agent for preventing and/or treating renal diseases.[Means for Solution]The present inventors have conducted extensive studies on compounds having a trypsin inhibitory action, and as a result, they have found that a guanidinobenzoic acid compound has a trypsin inhibitory action, thereby completing the present invention. The guanidinobenzoic acid compound of the present invention can be used as an agent for preventing and/or treating renal disease as an agent which will substitute low-protein diet therapy, and an agent for preventing and/or treating trypsin-related diseases, for example, pancreatitis, gastroesophageal reflux disease, hepatic encephalopathy, influenza, and the like.
摘要翻译: [问题]提供可用作预防和/或治疗肾脏疾病的药剂的化合物。 [解决方案]本发明人对具有胰蛋白酶抑制作用的化合物进行了广泛的研究,结果发现胍基苯甲酸化合物具有胰蛋白酶抑制作用,从而完成了本发明。 本发明的胍基苯甲酸化合物可以用作预防和/或治疗肾脏疾病的药剂,作为代替低蛋白饮食疗法的药剂,以及用于预防和/或治疗胰蛋白酶相关疾病的药剂,例如 ,胰腺炎,胃食管反流病,肝性脑病,流行性感冒等。
-
公开(公告)号:US08524727B2
公开(公告)日:2013-09-03
申请号:US12933137
申请日:2010-03-29
申请人: Yuji Matsushima , Hirokazu Kubota , Hisao Hamaguchi , Yoshinori Okamoto , Takeshi Hondo , Fusako Nishigaki
发明人: Yuji Matsushima , Hirokazu Kubota , Hisao Hamaguchi , Yoshinori Okamoto , Takeshi Hondo , Fusako Nishigaki
IPC分类号: A01N43/54 , A61K31/505
CPC分类号: C07D239/42 , C07D239/34 , C07D239/38 , C07D239/48 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/06 , C07D451/04 , C07D453/02 , C07D491/107 , C07D493/08
摘要: A novel and excellent method for preventing and/or treating diseases related to a cannabinoid type 2 receptor, based on an agonistic action on a cannabinoid type 2 receptor. It was found that a hetero ring derivative mainly having two substituents, for example, a pyrimidine-5-carboxamide derivative having a substituent amino group at the 2-position, exhibits a potent agonistic action on a cannabinoid type 2 receptor, and can be an agent for preventing and/or treating diseases related to a cannabinoid type 2 receptor such as inflammatory diseases, pain, and the like.
摘要翻译: 基于对大麻素2型受体的激动作用,预防和/或治疗与大麻素2型受体相关的疾病的新颖且优异的方法。 发现主要具有两个取代基的杂环衍生物,例如2-位具有取代基氨基的嘧啶-5-甲酰胺衍生物对大麻素2型受体表现出强烈的激动作用,并且可以是 用于预防和/或治疗与大麻素2型受体相关的疾病如炎性疾病,疼痛等的药剂。
-
公开(公告)号:US08311371B2
公开(公告)日:2012-11-13
申请号:US11884407
申请日:2006-02-16
申请人: Kenji Kawano , Masaya Nanami , Hiroaki Senda , Takeshi Hondo , Seiji Uchida , Yuji Sato , Toru Nakahira
发明人: Kenji Kawano , Masaya Nanami , Hiroaki Senda , Takeshi Hondo , Seiji Uchida , Yuji Sato , Toru Nakahira
CPC分类号: G02F1/2255 , G02F1/0356 , G02F2001/212 , G02F2202/07 , G02F2202/20
摘要: Herein disclosed is an optical modulation device, comprising: a substrate 1 having a polarization non-reversal region 17a and a polarization reversal region 17b; an optical waveguide 18 including first and second branched optical waveguide portions 18a, 18b; and a traveling waveguide including a center electrode 19a and a ground electrode 19b, 19c to have an electric signal applied thereto, said traveling waveguide and said first and second branched optical waveguide portions collectively forming an interaction portion to have said incident light interacted with said electric signal, said interaction portion being constituted by a first interaction sub-portion 20a and a second interaction sub-portion 20b, said first and second interaction sub-portions being respectively positioned in regions of said substrate having opposite polarization orientations with each other, in which said center electrode is positioned in face to face relationship with one of said first and second branched optical waveguide portions at said first and second interaction sub-portion to ensure that said incident light in said first and second branched optical waveguide portions are phase modulated, and in which said interaction portion includes an optical waveguide shift sub-portion sandwiched between said first and second interaction sub-portions to have positions of said first and second branched optical waveguide portions shifted therein in a transverse direction, ensuring that positions of said first and second optical waveguides relative to said center and ground electrodes are interchanged between said first and second interaction sub-portions.
摘要翻译: 这里公开了一种光调制装置,包括:具有极化非反转区域17a和极化反转区域17b的基板1; 包括第一和第二分支光波导部分18a,18b的光波导18; 以及具有施加电信号的中心电极19a和接地电极19b,19c的行进波导,所述行波导管和所述第一和第二分支光波导部分共同形成相互作用部分,以使所述入射光与所述电 信号,所述相互作用部分由第一相互作用子部分20a和第二相互作用子部分20b构成,所述第一相互作用子部分和第二相互作用子部分分别位于具有相反极化取向的所述基板的区域中,其中 所述中心电极在所述第一和第二相互作用子部分处于与所述第一和第二分支光波导部分中的一个相对面的关系,以确保所述第一和第二分支光波导部分中的所述入射光被相位调制,以及 其中所述相互作用部分包括光波导s 夹在所述第一相互作用子部分和第二相互作用子部分之间的折叠部分,以使所述第一和第二分支光波导部分在横向上移位的位置,确保所述第一和第二光波导相对于所述中心和接地电极的位置 在所述第一和第二相互作用子部分之间互换。
-
公开(公告)号:US20110053912A1
公开(公告)日:2011-03-03
申请号:US12933137
申请日:2010-03-29
申请人: Yuji Matsushima , Hirokazu Kubota , Hisao Hamaguchi , Yoshinori Okamoto , Takeshi Hondo , Fusako Nishigaki
发明人: Yuji Matsushima , Hirokazu Kubota , Hisao Hamaguchi , Yoshinori Okamoto , Takeshi Hondo , Fusako Nishigaki
IPC分类号: A61K31/55 , C07D405/12 , A61K31/506 , A61P29/00 , C07D413/12 , A61K31/5377 , C07D417/12 , A61K31/541 , C07D491/107 , C07D417/14
CPC分类号: C07D239/42 , C07D239/34 , C07D239/38 , C07D239/48 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/06 , C07D451/04 , C07D453/02 , C07D491/107 , C07D493/08
摘要: A novel and excellent method for preventing and/or treating diseases related to a cannabinoid type 2 receptor, based on an agonistic action on a cannabinoid type 2 receptor. It was found that a hetero ring derivative mainly having two substituents, for example, a pyrimidine-5-carboxamide derivative having a substituent amino group at the 2-position, exhibits a potent agonistic action on a cannabinoid type 2 receptor, and can be an agent for preventing and/or treating diseases related to a cannabinoid type 2 receptor such as inflammatory diseases, pain, and the like.
摘要翻译: 基于对大麻素2型受体的激动作用,预防和/或治疗与大麻素2型受体相关的疾病的新颖且优异的方法。 发现主要具有两个取代基的杂环衍生物,例如2-位具有取代基氨基的嘧啶-5-甲酰胺衍生物对大麻素2型受体表现出强烈的激动作用,并且可以是 用于预防和/或治疗与大麻素2型受体相关的疾病如炎性疾病,疼痛等的药剂。
-
-
-
-
-
-
-
-
-